Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III neoadjuvant nab-paclitaxel vs solvent-based paclitaxel in early breast cancer
2011-004714-41Phase 3Completed
- Sponsor
- GBG Forschungs
- Start
- Apr 2012
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of nab-paclitaxel in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Pathological complete response (pCR, ypT0 ypN0). Started Apr 2012; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-004714-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004714-41.